TY - JOUR
T1 - The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016
T2 - A summary
AU - Kramer, Anneke
AU - Pippias, Maria
AU - Noordzij, Marlies
AU - Stel, Vianda S.
AU - Andrusev, Anton M.
AU - Aparicio-Madre, Manuel I.
AU - Arribas Monzón, Federico E.
AU - Åsberg, Anders
AU - Barbullushi, Myftar
AU - Beltrán, Palma
AU - Bonthuis, Marjolein
AU - Caskey, Fergus J.
AU - Castro De La Nuez, Pablo
AU - Cernevskis, Harijs
AU - De Meester, Johan
AU - Finne, Patrik
AU - Golan, Eliezer
AU - Heaf, James G.
AU - Hemmelder, Marc H.
AU - Ioannou, Kyriakos
AU - Kantaria, Nino
AU - Komissarov, Kirill
AU - Korejwo, Grzegorz
AU - Kramar, Reinhard
AU - Lassalle, Mathilde
AU - Lopot, František
AU - Macário, Fernando
AU - Mackinnon, Bruce
AU - Pálsson, Runólfur
AU - Pechter, Ülle
AU - Piñera, Vicente C.
AU - De Pablos, Carmen Santiuste
AU - Segarra-Medrano, Alfons
AU - Seyahi, Nurhan
AU - Roblero, Maria F.Slon
AU - Stojceva-Taneva, Olivera
AU - Vazelov, Evgueniy
AU - Winzeler, Rebecca
AU - Ziginskiene, Edita
AU - Massy, Ziad
AU - Jager, Kitty J.
N1 - Funding Information:
The ERA-EDTA Registry is funded by the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA). This article was written by Anneke Kramer et al. on behalf of the ERA-EDTA Registry, which is an official body of the ERA-EDTA. In addition, Dr. Caskey reports fund- ing from the National Health Service during the conduct of the study. Dr. Finne reports personal fees from Baxter, outside the submitted work and Dr. Slon Roblero reports personal fees from NxStage, outside the submitted work.
Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.
PY - 2019/2/6
Y1 - 2019/2/6
N2 - Background: This article summarizes the ERA-EDTA Registry's 2016 Annual Report, by describing the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2016 within 36 countries. Methods: In 2017 and 2018, the ERA-EDTA Registry received data on patients undergoing RRT for ESRD in 2016 from 52 national or regional renal registries. In all, 32 registries provided individual patient data and 20 provided aggregated data. The incidence and prevalence of RRT and the survival probabilities of these patients were determined. Results: In 2016, the incidence of RRT for ESRD was 121 per million population (pmp), ranging from 29 pmp in Ukraine to 251 pmp in Greece. Almost two-thirds of patients were men, over half were aged ≥65 years and almost a quarter had diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 84% of patients. On 31 December 2016, the prevalence of RRT was 823 pmp, ranging from 188 pmp in Ukraine to 1906 pmp in Portugal. In 2016, the transplant rate was 32 pmp, varying from 3 pmp in Ukraine to 94 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2007-11, the 5-year unadjusted patient survival probability on all RRT modalities combined was 50.5%. For 2016, the incidence and prevalence of RRT were higher among men (187 and 1381 pmp) than women (101 and 827 pmp), and men had a higher rate of kidney transplantation (59 pmp) compared with women (33 pmp). For patients starting dialysis and for patients receiving a kidney transplant during 2007-11, the adjusted patient survival probabilities appeared to be higher for women than for men.
AB - Background: This article summarizes the ERA-EDTA Registry's 2016 Annual Report, by describing the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2016 within 36 countries. Methods: In 2017 and 2018, the ERA-EDTA Registry received data on patients undergoing RRT for ESRD in 2016 from 52 national or regional renal registries. In all, 32 registries provided individual patient data and 20 provided aggregated data. The incidence and prevalence of RRT and the survival probabilities of these patients were determined. Results: In 2016, the incidence of RRT for ESRD was 121 per million population (pmp), ranging from 29 pmp in Ukraine to 251 pmp in Greece. Almost two-thirds of patients were men, over half were aged ≥65 years and almost a quarter had diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 84% of patients. On 31 December 2016, the prevalence of RRT was 823 pmp, ranging from 188 pmp in Ukraine to 1906 pmp in Portugal. In 2016, the transplant rate was 32 pmp, varying from 3 pmp in Ukraine to 94 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2007-11, the 5-year unadjusted patient survival probability on all RRT modalities combined was 50.5%. For 2016, the incidence and prevalence of RRT were higher among men (187 and 1381 pmp) than women (101 and 827 pmp), and men had a higher rate of kidney transplantation (59 pmp) compared with women (33 pmp). For patients starting dialysis and for patients receiving a kidney transplant during 2007-11, the adjusted patient survival probabilities appeared to be higher for women than for men.
KW - Dialysis
KW - End-stage renal disease
KW - Epidemiology
KW - Kidney transplantation
KW - Survival analysis
UR - http://www.scopus.com/inward/record.url?scp=85073254942&partnerID=8YFLogxK
U2 - 10.1093/ckj/sfz011
DO - 10.1093/ckj/sfz011
M3 - Article
AN - SCOPUS:85073254942
SN - 2048-8505
VL - 12
SP - 702
EP - 720
JO - Clinical Kidney Journal
JF - Clinical Kidney Journal
IS - 5
ER -
